Metronidazole-Associated Yeast Infections

Mechanism and Risk

Metronidazole is primarily used to treat trichomoniasis and bacterial vaginosis, with high efficacy rates of approximately 95% 1, 2
When metronidazole eliminates anaerobic bacteria, it can disrupt the normal vaginal microbiome, creating conditions favorable for yeast overgrowth 3, 4

Typical symptoms of vulvovaginal candidiasis include pruritus (itching) and vaginal discharge 3, 5
Other symptoms may include vaginal soreness, vulvar burning, dyspareunia (painful intercourse), and external dysuria 4
Candida vaginitis is associated with a normal vaginal pH (≤4.5), unlike bacterial vaginosis or trichomoniasis 5
Diagnosis can be confirmed by wet preparation or Gram stain showing yeasts or pseudohyphae, or by culture 3

Approximately 10-20% of women normally harbor Candida species in the vagina without symptoms, but antibiotics like metronidazole can trigger symptomatic infection 4
For patients who develop yeast infections after metronidazole treatment, topical azole medications are more effective than nystatin 5
Treatment options include various intravaginal formulations such as clotrimazole, miconazole, or oral fluconazole 5
When treating trichomoniasis with metronidazole, clinicians should be aware of the potential for secondary yeast infections and counsel patients accordingly 2

Women with a history of recurrent yeast infections may be at higher risk when taking metronidazole 4
Monitoring for symptoms of yeast infection is important during and after metronidazole therapy 2

The risk of yeast infection should not preclude the use of metronidazole when indicated, as it remains the first-line treatment for trichomoniasis and bacterial vaginosis 1
The benefits of treating infections like trichomoniasis generally outweigh the risk of developing a yeast infection 2